Loading clinical trials...
Loading clinical trials...
The anti-CD20 monoclonal antibodies, rituximab (R) and obinutuzumab (G), are used as standard maintenance therapy every 2 months for 2 to 3 years in patients with follicular lymphoma (FL) or mantle ce...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Centre Henri Becquerel
NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
NCT06191744 · Follicular Lymphoma (FL)
NCT06263491 · Mantle Cell Lymphoma
NCT07545603 · Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, and more
NCT06252675 · Mantle Cell Lymphoma
Centre Henri Becquerel
Rouen
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions